Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2021-11-16 00:00:00 ET · period of report 2021-11-15 · accession 0001867096-21-000080 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2021-11-16 | 2021-11-15 | XERS | Edick Paul R | See Remarks, Dir | P - Purchase | $2.28 | +20.0K | 33.4K | +149% | +$45.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-15 | P | A | 20,000 | $2.28 | 33,430 | I By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 | — | — | (F1) The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.275 to $2.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. (F2) The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |